Prophylaxis and Management of Invasive Fungal Infections in Older Patients with Acute Myelogenous Leukemia

Sponsored by North American Center for Continuing Medical Education, LLC

Presenter/Q&A Cohosts

Amar Safdar, MD
Associate Professor of Medicine
Department of Infectious Diseases, Infection Control and Employee Health
The University of Texas MD Anderson Cancer Center
Houston, Texas

Jeffrey D. Dunn, PharmD, MBA
Formulary and Contract Manager
SelectHealth, Inc
Salt Lake City, Utah

Target Audience

This activity is designed for managed markets physicians and pharmacists.

Learning Objectives

After completing this activity, participants should be able to:

Identify the clinical and economic burden of invasive fungal infections in older patients with acute myelogenous leukemia (AML)
Describe the clinical presentation of invasive fungal infections in older patients with AML and the role of diagnostic assays
Summarize the risk-versus-benefit profiles of traditional and new agents and combinations for preventing and managing invasive fungal infections in older patients with AML
Incorporate guidelines and evidence to assist clinicians in optimizing outcomes associated with invasive fungal infections in older patients with AML

Activity Overview

This on-demand slide lecture with audio is available with html slides, the presentation transcript, and a Q&A session transcript.

To be eligible for documentation of credit, participants must participate in the full activity, complete the 10-question online post-test with a score of 70% or better, and complete the evaluation form. After successful completion of the post-test and evaluation form online at www.naccme.com, participants may immediately print their documentation of credit.

This educational activity is a knowledge-based activity.

There is no fee associated with this activity.

Participants who have successfully completed the live version of this activity are not eligible to receive credit for this activity.

Release Date: July 14, 2009

Expiration Date: July 14, 2010

Estimated time to complete: 1 hour

For questions regarding this educational activity, please contact Angela Scarnici at 609-371-1137.

Hardware/Software Requirements

All educational activities are accessible via a computer with 650 MHz PC, 128 MB RAM, Windows or MAC operating system, Internet Explorer, Netscape, or Safari browsers. Windows Media Player, sound card, and speakers are required for streamed audio. Flash Player, sound card, and speakers are required for video programs. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.

CME Accreditation

North American Center for Continuing Medical Education, LLC (NACCME) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NACCME designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CPE Accreditation

North American Center for Continuing Medical Education, LLC (NACCME) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is approved for 1 contact hour (0.1 CEU) of continuing pharmacy education (UAN 276-000-09-003-H01-P).

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact John Savage, Director, Medical Education, NACCME, in writing at 300 Rike Drive, Suite A, Millstone Township, NJ 08535, or by e-mail at jsavage@naccme.com. The Director of Medical Education will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Vice President, Medical Education, NACCME, may be made for a second level of review.

Independent Clinical Reviewer: Michael E. Kleinberg, MD, PhD, Associate Professor, Department of Medicine, University of Maryland School of Medicine, Head, Infectious Diseases Section, University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, Maryland

Planning Committee

The planning committee comprises Jeffrey D. Dunn, PharmD, MBA, and Amar Safdar, MD; Michael E. Kleinberg, MD, PhD; and Mary Johnson, Stacey Ohana, Randy Robbin, and John Savage, NACCME.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty has reported the following:
Dr. Dunn: Advisory board—AstraZeneca, Bayer HealthCare Pharmaceuticals, Celgene, Takeda
Dr. Kleinberg: Grant/research support—Pfizer
Dr. Safdar: Grant/research support—Bayer HealthCare Pharmaceuticals, Berlex, Enzon; Promotional speakers bureau—Cubist, Enzon, Merck, Pfizer

Ms. Johnson, Ms. Ohana, Mr. Robbin, and Mr. Savage have disclosed no relevant financial relationships with any commercial interests.

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.

The faculty has disclosed the following off-label/unapproved use(s) of drugs and/or devices will be discussed: The use of antifungal combination therapy and granulocyte macrophage colony stimulating factor for the treatment of bacterial and fungal infections.

Privacy Policy

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME maintains physcal, electronic and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2009 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education.

Grant Support

Supported by an educational grant from Bayer HealthCare Pharmaceuticals.